ABCC5 and colorectal carcinoma: These studies also demonstrated that, in addition to 5-FU, MRP5 also confers resistance in CRC to several anticancer agents, including methotrexate, pemetrexed, doxorubicin, and the platinum-containing drugs cisplatin and oxaliplatin [104].